Evaluation of response to tyrosine kinase inhibitors in renal cell carcinoma patients based on expression of miR-99b, -144, -210, -222, -302а and -377 in tumor tissue.

Autor:	Vitruk Yu V; National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine., Semko SL; National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine., Voylenko OA; National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine., Pikul MV; National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine., Borikun TV; R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NASU, Kyiv 03022, Ukraine., Zadvornyi TV; R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NASU, Kyiv 03022, Ukraine., Yalovenko TM; R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NASU, Kyiv 03022, Ukraine., Stakhovsky EO; National Cancer Institute, Ministry of Health of Ukraine, Kyiv 03022, Ukraine., Rossylna OV; Clinic for Personalized Diagnostics and Therapy Design 'Oncotheranostics', Kyiv 03022, Ukraine.
Jazyk:	angličtina
Zdroj:	Experimental oncology [Exp Oncol] 2021 Jun; Vol. 43 (2), pp. 98-103.
DOI:	10.32471/exp-oncology.2312-8852.vol-43-no-2.16383
Abstrakt:	Background: Renal cell carcinoma (RCC) is one of the most common solid tumors in adults highly resistant to conventional therapies. The expression profile of a number of miRNAs correlates with RCC response to chemotherapeutic agents. Aim: To identify the association of tumor miRNAs expression with neoadjuvant treatment response in patients with RCC. Materials and Methods: We analyzed the expression levels of tumor miR-99b, -144, -155, -210, -222, -302а, -377 in 93 RCC patients who received pazopanib or sunitinib in neoadjuvant regimen using RT-PCR. RNU48 was used as a reference miRNA. Results: The levels of expression of miR-99b and -377 are associated with the RCC response to pazopanib, and microRNA-210 and -377 to sunitinib. The characteristic expression profile of miR-99b, -144, -222, -377, and miR-302a determined in 90% of cases was delineated in pazopanib responders as opposed to nonresponders. Similarly, the characteristic expression profile of miR-210, -222, -302a and -377 was suggested for sunitinib responders. Conclusions: Levels of miR-99b, -210 and -377 expression in RCC tumor tissue might be used as a basis for future predictive panel intended for the assessment of the sensitivity to the regimens of neoadjuvant RCC treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu